After radioiodine treatment for Graves' disease, most patients show one of three patterns in their thyroid hormone levels over the next year: a dip then rise, a rise then dip then rise again, or a steady decline. The lowest point in these patterns and how much hormones recover from it reliably predict whether the patient will end up with normal, low, or high thyroid function.
Claim Context
Among patients with Graves' disease treated with radioiodine therapy, three distinct patterns of serum thyroid hormone changes emerge over one year: the valley pattern (67%), characterized by an initial decline followed by a rebound; the mountain pattern (17%), featuring an initial rise, then a drop with a subsequent rebound; and the downhill pattern (16%), showing a gradual, sustained decline without a clear nadir. These patterns predict the final euthyroid, hypothyroid, or hyperthyroid state in 86% of patients with valley or mountain trajectories, enabling clinical prediction of long-term thyroid function based on early hormonal trends.
“The late patterns were a stable state after an initial decrease with a bottom followed by an increase (valley pattern) in 47 (67%), a stable state after an initial increase with a peak followed by a decrease with a bottom and a subsequent re-increase (mountain pattern) in 12 (17%) and a late stable state after a gradual slow decrease without an obvious bottom near or till one year (downhill pattern) in 11 (16%). The bottom level and the degree of hormonal recovery from the bottom determined the stable euthyroid, hypothyroid or hyperthyroid state in 49 (86%) of 57 with the valley or mountain pattern.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of multiple cohort studies would establish whether these three patterns are consistently reproducible across diverse populations and whether they reliably predict long-term thyroid outcomes with pooled effect estimates.
A systematic review and meta-analysis of all prospective cohort studies reporting serial thyroid hormone measurements in adults with Graves' disease treated with radioiodine therapy, including at least 10 studies with >50 patients each, standardized timepoints (0, 1, 3, 6, 9, 12 months), and predefined definitions of euthyroid/hypothyroid/hyperthyroid states based on TSH, FT4, FT3 thresholds. Primary outcome: pooled prevalence of valley, mountain, and downhill patterns and their positive predictive value for final thyroid status.
An RCT could test whether modifying early hormonal trajectories (e.g., with temporary antithyroid drugs) alters the likelihood of developing a specific long-term outcome, thereby testing whether the patterns are modifiable predictors.
A double-blind RCT of 300 adults with newly diagnosed Graves' disease, randomized to receive radioiodine therapy alone vs. radioiodine plus 3 months of methimazole to blunt early hormone surges. Primary outcome: proportion of patients developing valley, mountain, or downhill patterns at 6 months and final thyroid status at 12 months. Secondary outcomes: time to euthyroidism, need for levothyroxine.
A larger, multi-center prospective cohort could validate the generalizability of these three patterns across different populations, dosing regimens, and baseline characteristics.
A prospective multicenter cohort study of 500 adults with Graves' disease undergoing radioiodine therapy, with monthly thyroid hormone measurements for 12 months, standardized radioiodine dosing based on thyroid volume and uptake, and blinded outcome adjudication. Primary outcome: incidence and predictive value of valley, mountain, and downhill patterns for final thyroid status.
A case-control study could compare patients who developed hypothyroidism vs. those who remained euthyroid to identify whether specific early hormonal trajectories (e.g., depth of nadir, speed of rebound) differ between groups.
A case-control study comparing 100 patients who became hypothyroid within 12 months of radioiodine therapy to 100 matched euthyroid controls, matched for age, sex, baseline TSH, and radioiodine dose. Exposure: detailed serial hormone trajectories from 0–6 months. Primary analysis: odds ratio for hypothyroidism associated with valley pattern vs. other patterns.
A cross-sectional study could assess whether patients with known long-term outcomes (e.g., hypothyroidism at 2 years) retrospectively fit one of the three patterns based on single timepoint hormone levels.
A cross-sectional analysis of 200 patients with Graves' disease who received radioiodine therapy 18–24 months prior, grouped by final thyroid status. Hormone levels measured at a single timepoint (e.g., 6 months post-therapy) and compared across groups to see if early nadir or rebound levels correlate with later outcomes.